FORM D	UNITED STATES		OMB APPROVAL
	SECURITIES AND EXCHANGE COMMISSION	> 2	SOMB Number: 3235-0076
	Washington, D.C. 20549	BECEIVED	Expires: December 31, 1996
	FORM D	N 1 6 -	Estimated average burden hours per form
	FORM D	Y 12200	
1881 HEL BIEN (888) HAT (8018 1888 1881 8810 1811	NOTICE OF SALE OF SECURITIES	-	SEC USE ONLY
	PURSUANT TO REGULATION D,	155	Prefix Serial
	SECTION 4(6), AND/OR		FICHX Schal
03058719	UNIFORM LIMITED OFFERING EXEMPTION		DATE RECEIVED
Name of Offering (check if this is an amen Sale of Series B Convertible Preferred Stock	dment and name has changed, and indicate change.)		1116606
Filing Under (Check box(es) that apply): ☐ Ru Type of Filing: ☐ New Filing ☐ Arr	lle 504 □ Rule 505 □ Rule 506 □ Section 4(6 nendment) ULO	PPOCESSE
	A. BASIC IDENTIFICATION DATA		4 0000
1. Enter the information requested about the is	suer		MAY 1 4 Z003
Name of Issuer (☐ check if this is an amendment Pintex Pharmaceuticals, Inc.	ent and name has changed, and indicate change.)		THOMSON FINANCIAL
Address of Executive Offices 313 Pleasant Street, Watertown, MA 02472	(Number and Street, City, State, Zip Code)	Telephone (617) 924-9	Number (Including Area Code) 9200
Address of Principal Business Operations (if different from Executive Offices)	(Number and Street, City, State, Zip Code)	Telephone	Number (Including Area Code)
Brief Description of Business Research for cancer diagnostics.			
Type of Business Organization			
☑ corporation☐ business trust	☐ limited partnership, already formed☐ limited partnership, to be formed☐		other (please specify):
Actual or Estimated Date of Incorporation or O	rganization: Month Year 9 9		☐ Estimated
Jurisdiction of Incorporation or Organization:	(Enter two-letter U.S. Postal Service abbreviation for Stat	te:	
·	CN for Canada; FN for other foreign jurisdiction)		DE

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6).

When to File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

AT	TEN	ITV	ON
----	-----	-----	----

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

		A. BASIC IDEN	TIFICATION DATA		_		
2. Enter the information i	equested for the follo	owing:					
 Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and 							
	managing partner of p						
Check Box(es) that Apply:	☐ Promoter	⊠ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner		
Full Name (Last name first, Dr. Walter Gilbert	if individual)						
Business or Residence Addr c/o Harvard University Bio			mbridge, MA 02138				
Check Box(es) that Apply:	☐ Promoter	⊠ Beneficial Owner	☐ Executive Officer	Director	General and/or Managing Partner		
Full Name (Last name first, BioVentures Investors Lin							
Business or Residence Addr 245 First Street, 14th Floor							
Check Box(es) that Apply:	☐ Promoter	⊠ Beneficial Owner	☐ Executive Officer	Director	☐ General and/or Managing Partner		
Full Name (Last name first, Canaan Equity II L.P.	if individual)						
Business or Residence Addr 105 Rowayton Avenue, Ro		eet, City, State, Zip Code)					
Check Box(es) that Apply:	Promoter	⊠ Beneficial Owner	☐ Executive Officer	Director	☐ General and/or Managing Partner		
Full Name (Last name first, Canaan Equity II L.P. (QP							
Business or Residence Address 105 Rowayton Avenue, Ro		eet, City, State, Zip Code)					
Check Box(es) that Apply:	Promoter		☐ Executive Officer	Director	☐ General and/or Managing Partner		
Full Name (Last name first, Canaan Equity II Entrepre	if individual) eneurs LLC						
Business or Residence Address 105 Rowayton Avenue, Ro	•	eet, City, State, Zip Code)					
Check Box(es) that Apply:	☐ Promoter	⊠ Beneficial Owner			☐ General and/or Managing Partner		
Full Name (Last name first, Dr. Janusz Sowadski	,						
Business or Residence Addre c/o Pintex Pharmaceuticals			2472				
Check Box(es) that Apply:	Promoter	☑ Beneficial Owner	☐ Executive Officer	Director	☐ General and/or Managing Partner		
Full Name (Last name first, xiao Zhen Zhou	f individual)						
Business or Residence Addre c/o Pintex Pharmaceuticals			2472				

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

Check Box(es) that Apply:	Promoter	⊠ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, i Wieslawa P. Sowadska	f individual)				
Business or Residence Addre c/o Pintex Pharmaceuticals			02472		
Check Box(es) that Apply:	☐ Promoter	⊠ Beneficial Owner	☐ Executive Officer		☐ General and/or Managing Partner
Full Name (Last name first, i Dr. Seth Rudnick	f individual)				
Business or Residence Addre c/o Canaan Equity II L.I			5853		
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	General and/or Managing Partner
Full Name (Last name first, i Dr. Kun Ping Lu					
Business or Residence Addre c/o Pintex Pharmaceuticals			02472		
Check Box(es) that Apply:	☐ Promoter	⊠ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, in Peter Lawrence					
Business or Residence Addre			16		
Check Box(es) that Apply:	Promoter	⊠ Beneficial Owner	☐ Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, it Marc Goldberg	findividual)				
Business or Residence Addre c/o BioVentures Investors I			loor, Cambridge, MA 02142		
Check Box(es) that Apply:	☐ Promoter	⊠ Beneficial Owner	☐ Executive Officer	□ Director	General and/or Managing Partner
Full Name (Last name first, it Paul Kelly					
Business or Residence Addre c/o Zero Stage Capital, 101	'		2142		
Check Box(es) that Apply:	☐ Promoter	⊠ Beneficial Owner	☐ Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, it Zero Stage Capital VII, L.P	•				
Business or Residence Addre 101 Main Street, 17th Floor					
Check Box(es) that Apply:	Promoter	⊠ Beneficial Owner	☐ Executive Officer	Director	☐ General and/or Managing Partner
Full Name (Last name first, it Zero Stage Capital SBIC V	II L.P.				
Business or Residence Addre 101 Main Street, 17th Floor					
Check Box(es) that Apply:	☐ Promoter	⊠ Beneficial Owner	☐ Executive Officer	Director	☐ General and/or Managing Partner
Full Name (Last name first, if Zero Stage Capital (Caymar	,				
Business or Residence Addre 101 Main Street, 17th Floor	ss (Number and Str				
Check Box(es) that Apply:	☐ Promoter	⊠ Beneficial Owner	☐ Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, it	findividual)				

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

POD Holding, L.P.				
Business or Residence Address (Number and 18 Newbury Street, 3rd Floor, Boston, MA	•			
Check Box(es) that Apply: Promoter	⊠ Beneficial Owner	☐ Executive Officer	Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual) Collaborative Seed & Growth Partners, LL	.c			
Business or Residence Address (Number and 1340 Centre Street, Suite 207, Newton Cent				

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

					В.	INFORMA	ATION ABO	OUT OFFER	RING				
Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?									Yes No				
Answer also in Appendix, Column 2, if filing under ULOE.													
2.	What is	the minimu	ım investm	ent that wil	l be accepte	d from any	individual?						\$1,000
3. Does the offering permit joint ownership of a single unit?									************	Yes No □			
4. Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only. Not Applicable Full Name (Last name first, if individual)													
	(-		,										
Bus	iness or l	Residence A	ddress (Nu	ımber and S	treet, City,	State, Zip C	(ode)						
Nan	ne of Ass	ociated Bro	ker or Dea	ler	<u> </u>		 						
	. 117		1 7 7	0.11.11.1	T . 1	11 '- TD 1							·
Stat		ich Person I "All States" [AK] [IN] [NE] [SC]						[DE] [MD] [NC] [VA]	[DC] [MA] [ND] [WA]	[FL] [MI] [OH] [WV]	[GA] [MN] [OK] [WI]	[HI] [MS] [OR] [WY]	
Full		ast name fi						[, , , ,]	[(())	,	[]	[•]	[]
Bus	iness or I	Residence A	ddress (Nu	imber and S	treet, City,	State, Zip C	ode)						
Nan	ne of Ass	ociated Brol	ker or Deal	ler									
State	es in Wh	ich Person L	isted Has	Solicited or	Intends to S	Solicit Purch	nasers						
	(Check [AL] [IL] [MT] [RI]	"All States" [AK] [IN] [NE] [SC]	or check in [AZ] [IA] [NV] [SD]	ndividual St [AR] [KS] [NH] [TN]	(CA) [CA] [KY] [NJ] [TX]	[CO] [LA] [NM] [UT]	[CT] [ME] [NY] [VT]	[DE] [MD] [NC] [VA]	[DC] [MA] [ND] [WA]	[FL] [MI] [OH] [WV]	[GA] [MN] [OK] [WI]	[HI] [MS] [OR] [WY]	All States [ID] [MO] [PA] [PR]
Full	Name (I	ast name fir	st, if indiv	idual)									
Bus	iness or I	Residence A	ddress (Nu	ımber and S	treet, City,	State, Zip C	ode)						
Nan	ne of Ass	ociated Brol	ker or Deal	ler									<u> </u>
State	es in Wh	ch Person L	isted Has	Solicited or	Intends to S	Solicit Purch	nasers						
~ inti		"All States" [AK] [IN] [NE]					[CT] [ME] [NY]	[DE] [MD] [NC] [VA]	[DC] [MA] [ND] [WA]	[FL] [MI] [OH]	[GA] [MN] [OK] [WI]	[HI] [MS] [OR] [WY]	Ali States [ID] [MO] [PA] [PR]

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

	C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE O	F PROCEEDS	
1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.		
	Type of Security	Aggregate Offering Price	Amount Already Sold
	Debt	\$	
	Equity	\$	
	☐ Common ☑ Preferred	Ψ	Ψ <u></u>
	Common & Preferred		
	Convertible Securities (including warrants) – Series B Convertible Preferred Stock	\$ <u>7,650,000</u>	\$ <u>7,650,000</u>
	Partnership Interests	\$	
	Other (Specify)	\$	\$
	Total	\$ 7,650,000	\$ _ 7,650,000
2.		Number of Investors	Aggregate Dollar Amount of Purchases
	Accredited Investors	11	\$ 7,650,000
			\$ 7,030,000
	Non-accredited Investors.	_	_ \$
	Total (for filings under Rule 504 only)		
	Answer also in Appendix, Column 4, if filing under ULOE.		
3.	If this filing is for an offering under Rule 504 or 505, enter the information for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1.		5.11
	Type of Offering	Type of Security	Dollar Amount Sold
	Rule 505	•	\$
	Regulation A		<u> </u>
	Rule 504		•
	Total		- \$
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees		\$
	Printing and Engraving Costs		\$
	Legal Fees	٥	\$ 28,000
	Accounting Fees		3 \$ 20,000
	Engineering Fees		\$
	Sales Commissions (specify finders' fees separately)		\$
	Other Expenses (identify)		\$
	Total	٥	≤ \$ <u>28,000</u>

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND	USE O	F PROCEEDS	
b. Enter the difference between the aggregate offering price given in response to Part C - Question 1 and expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted gross proce the issuer."	eds to		\$ 7,622,000
5. Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to be used for the purposes shown. If the amount for any purpose is not known, furnish an estimate and check to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds issuer set forth in response to Part C - Question 4.b above.	he box		
		Payments to Officers, Directors, & Affiliates	Payments To Others
Salaries and fees		\$	
Purchase of real estate		\$	\$
Purchase, rental or leasing and installation of machinery and equipment		\$	□ \$
Construction or leasing of plant buildings and facilities		\$	□ \$
Acquisition of other businesses (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger)		\$	\$
Repayment of indebtedness	. 🗆	\$	□ \$
Working capital		\$	⊠ \$ <u>7,622,000</u>
Other (specify):		\$	 \$
Column Totals Total Payments Listed (column totals added)		\$ \$ \times \frac{7.6}{2}	□ \$ ⊠ \$ <u>7,622,000</u>
D. FEDERAL SIGNATURE		····	
The issuer has duly caused this notice to be signed by the undersigned duly authorized pers following signature constitutes an undertaking by the issuer to furnish to the U.S. Securitie quest of its staff, the information furnished by the issuer to any non-accredited investor pursuant to para	s and	Exchange Commission	
Issuer (Print or Type) Pintex Pharmaceuticals, Inc. Signature WWW M. William	Date /	NAY 7	03
Name of Signer (Print or Type) Dr. Janusz Sowadski Tyle of Signer (Print or Type) President			
ATTENTION			
Intentional misstatements or omissions of fact constitute federal criminal v	iolatior	ns. (See 18 U.S.C.)	1001.)